Trade VRDN anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Viridian Therapeutics, Inc. (VRDN) is trading at US$23.17, down 2.97% today as of Aug 28, 13:58 EDT. The company has a market capitalisation of US$2.75B. Over the past 52 weeks, VRDN has traded between US$13.18 and US$34.29. On Syfe you can trade VRDN with $0 commission and add it to your watchlist.
| Previous close | US$23.88 |
|---|---|
| Market cap | US$2.75B |
| 52-week range | US$13.18 – US$34.29 |
| Volume | 839.63K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.
Year: 2014
Viridian Therapeutics' Lumvoa Could Start Generating More Meaningful Revenue in 2027, RBC Says
Jun 30, 3:53 PM · MT Newswires
Viridian Therapeutics, Inc. (VRDN) stock is trading at US$23.17, -2.97% from the previous close of US$23.88.
The market cap for Viridian Therapeutics, Inc. (VRDN) stock is approximately US$2.75B.
The 52-week high for Viridian Therapeutics, Inc. (VRDN) stock is US$34.29.
The 52-week low for Viridian Therapeutics, Inc. (VRDN) stock is US$13.18.
Viridian Therapeutics, Inc. (VRDN) does not currently pay a dividend.
Stay on top of VRDN
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
